Stevens TM, Kovalovsky AO, Velosa C et al (2015) Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study. Mod Pathol 28:1084–1100

Article  PubMed  CAS  Google Scholar 

Dettloff J, Seethala RR, Stevens TM et al (2017) Mammary Analog Secretory Carcinoma (MASC) involving the thyroid gland: a report of the First 3 cases. Head Neck Pathol 11:124–130

Article  PubMed  Google Scholar 

Reynolds S, Shaheen M, Olson G et al (2016) A case of primary mammary Analog Secretory Carcinoma (MASC) of the thyroid masquerading as papillary thyroid carcinoma: potentially more than a one off. Head Neck Pathol 10:405–413

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dogan S, Wang L, Ptashkin RN et al (2016) Mammary analog secretory carcinoma of the thyroid gland: a primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. Mod Pathol 29:985–995

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu EY, Lebastchi J, Marqusee E et al (2017) A case of primary secretory carcinoma of the thyroid with high-grade features. Histopathology 71:665–669

Article  PubMed  PubMed Central  Google Scholar 

Liao H, Khan A, Miron PM, Cornejo KM (2018) Mammary analogue secretory carcinoma of the thyroid mimicking locally advanced papillary thyroid carcinoma: a rare case report. Int J Surg Pathol 26:459–463

Article  PubMed  Google Scholar 

Asa SL, Mete O (2018) An unusual salivary gland tumor mimicking papillary thyroid carcinoma: Mammary Analog Secretory Carcinoma. Front Endocrinol (Lausanne) 9:555

Article  PubMed  Google Scholar 

Desai MA, Mehrad M, Ely KA et al (2019) Secretory carcinoma of the thyroid gland: report of a highly aggressive case clinically mimicking undifferentiated carcinoma and review of the literature. Head Neck Pathol 13:562–572

Article  PubMed  Google Scholar 

Huang NS, Cao YM, Lu ZW et al (2021) Mammary analog secretory carcinoma of the thyroid gland: a rare cancer harboring TRK fusion. Oral Oncol 115:105092

Article  PubMed  CAS  Google Scholar 

Chu YH, Dias-Santagata D, Farahani AA et al (2020) Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC). Mod Pathol 33:2186–2197

Article  PubMed  PubMed Central  CAS  Google Scholar 

Saliba M, Mohanty AS, Ho AL, Drilon A, Dogan S (2022) Secretory carcinoma of the thyroid in a 49-Year-old man treated with Larotrectinib: protracted clinical course of Disease despite the high-Grade histologic features. Head Neck Pathol 16:612–620

Article  PubMed  Google Scholar 

Demetri GD, De Braud F, Drilon A et al (2022) Updated Integrated Analysis of the efficacy and safety of Entrectinib in patients with NTRK Fusion-positive solid tumors. Clin Cancer Res 28:1302–1312

Article  PubMed  PubMed Central  CAS  Google Scholar 

Amin MB, Greene FL, Edge SB et al (2017) The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin 67:93–99

Article  PubMed  Google Scholar 

Chambers M, Nosé V, Sadow PM, Tafe LJ, Kerr DA (2021) Salivary-like tumors of the thyroid: a Comprehensive Review of three Rare Carcinomas. Head Neck Pathol 15:212–224

Article  PubMed  Google Scholar 

Strauss BL, Bratthauer GL, Tavassoli FA (2006) STAT 5a expression in the breast is maintained in secretory carcinoma, in contrast to other histologic types. Hum Pathol 37:586–592

Article  PubMed  CAS  Google Scholar 

Kawahara A, Taira T, Abe H et al (2015) Diagnostic utility of phosphorylated signal transducer and activator of transcription 5 immunostaining in the diagnosis of mammary analogue secretory carcinoma of the salivary gland: a comparative study of salivary gland cancers. Cancer Cytopathol 123:603–611

Article  PubMed  CAS  Google Scholar 

Kinnunen M, Liu X, Niemelä E et al (2023) The impact of ETV6-NTRK3 oncogenic gene fusions on Molecular and Signaling Pathway alterations. Cancers (Basel) ;15

Lee YC, Chen JY, Huang CJ et al (2020) Detection of NTRK1/3 rearrangements in papillary thyroid carcinoma using immunohistochemistry, fluorescent in situ hybridization, and Next-Generation sequencing. Endocr Pathol 31:348–358

Article  PubMed  CAS  Google Scholar 

Chu YH, Wirth LJ, Farahani AA et al (2020) Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. Mod Pathol 33:2458–2472

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hang JF, Lee YC (2023) How sensitive is Pan-TRK immunohistochemistry for detecting NTRK fusions in papillary thyroid carcinoma? Mod Pathol 36:100222

Article  PubMed  Google Scholar 

Rooper LM, Karantanos T, Ning Y et al (2018) Salivary secretory carcinoma with a Novel ETV6-MET Fusion: expanding the Molecular Spectrum of a recently described Entity. Am J Surg Pathol 42:1121–1126

Article  PubMed  Google Scholar 

Baněčková M, Thompson LDR, Hyrcza MD et al (2023) Salivary gland secretory carcinoma: clinicopathologic and genetic characteristics of 215 cases and proposal for a Grading System. Am J Surg Pathol 47:661–677

Article  PubMed  Google Scholar 

Guilmette J, Dias-Santagata D, Nosé V, Lennerz JK, Sadow PM (2019) Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family. Hum Pathol 83:50–58

Article  PubMed  CAS  Google Scholar 

Sasaki E, Masago K, Fujita S et al (2020) Salivary secretory carcinoma harboring a Novel ALK Fusion: expanding the molecular characterization of Carcinomas beyond the ETV6 gene. Am J Surg Pathol 44:962–969

Article  PubMed  Google Scholar 

Shonka DC Jr., Ho A, Chintakuntlawar AV et al (2022) American Head and Neck Society Endocrine Surgery Section and international thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment. Head Neck 44:1277–1300

Article  PubMed  PubMed Central  Google Scholar 

Xu B, Viswanathan K, Umrau K et al (2022) Secretory carcinoma of the salivary gland: a multi-institutional clinicopathologic study of 90 cases with emphasis on grading and prognostic factors. Histopathology 81:670–679

Article  PubMed  PubMed Central  Google Scholar 

Hong DS, DuBois SG, Kummar S et al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21:531–540

Article  PubMed  PubMed Central  CAS  Google Scholar 

Drilon A, Li G, Dogan S et al (2016) What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol 27:920–926

Article  PubMed  PubMed Central  CAS  Google Scholar 

Drilon A, Ou SI, Cho BC et al (2018) Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent- front mutations. Cancer Discov 8:1227–1236

Article  PubMed  CAS  Google Scholar 

Drilon A, Nagasubramanian R, Blake JF et al (2017) A next-generation TRK kinase inhibitor overcomes Acquired Resistance to prior TRK kinase inhibition in patients with TRK Fusion-positive solid tumors. Cancer Discov 7:963–972

Article  PubMed  PubMed Central  CAS  Google Scholar 

Robinson JT, Thorvaldsdottir H, Turner D, Mesirov JP (2022) igv.js: an embeddable JavaScript implementation of the Integrative Genomics viewer (IGV). Bioinformatics ;39